2021 Impact Report and 2022 Goals


  • Jim Minow, Executive Director of Cure JM
  • Andrew Heaton, PhD, Chief Science Officer
  • Shannon Malloy, Director of Development and Family Engagement
Doctor and young juvenile myositis patient.

What is Juvenile Myositis?

Juvenile myositis, including juvenile dermatomyositis and juvenile polymyositis, is a group of rare and life-threatening autoimmune diseases, in which the body’s immune system attacks its own cells and tissues.

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.

Cure JM supports families, patients, and the juvenile myositis research community.